Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 clazosentan for prevention of delayed cerebral ischemia-related clinical deterioration after aneurysmal subarachnoid hemorrhage
2018-000241-39Phase 3Completed
- Sponsor
- Idorsia
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in subarachnoid hemorrhage (SAH) comparing Clazosentan with Placebo (2 arms). Primary endpoint: Occurrence of clinical deterioration due to delayed cerebral ischemia. Started Jul 2018; status: completed.
02
Drugs
clazosentan
03
Conditions
subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on 2018-000241-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000241-39.